NEUROSENSE THERAPEUTICS LTD.

(NRSN)
  Report
Delayed Nasdaq  -  04:00 2022-08-12 pm EDT
2.130 USD   +5.97%
08/02NEUROSENSE THERAPEUTICS : Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study - Form 6-K
PU
08/02NeuroSense Joins Everything ALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
CI
08/02NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study
PR
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NeuroSense Therapeutics Ltd. Reports Positive Results from Stage III ALS Biomarker Study

06/27/2022 | 08:30am EDT

NeuroSense Therapeutics L. announced results from Stage III of its biomarker study conducted in collaboration with Massachusetts General Hospital to evaluate PrimeC, NeuroSense's lead combination drug candidate for the treatment of amyotrophic lateral sclerosis. PrimeC is currently being evaluated in NeuroSense's Phase IIb PARADIGM study following the successful conclusion of its Phase IIa study which met its primary endpoints. The purpose of the initial ALS biomarker study was to characterize the baseline phenomena observed in people living with ALS. The study identified novel ALS biomarkers that are indicative of PrimeC's mechanism of action, via an analysis comparing blood samples obtained from healthy people and from people living with ALS. TDP-43 accumulation and neuroinflammation via prostagladin2 were amongst the disease-modifying targets characterized, along with miRNA dysregulation, iron accumulation, lysosomal dysfunction, and impaired autophagy. Stage II investigated the therapeutic effect of PrimeC. In NeuroSense's Phase IIa study, blood samples were analyzed to determine the longitudinal effect of PrimeC on the biomarkers identified in Stage I. Following 12 months of administration with PrimeC, statistically significant changes in key ALS-related biomarkers were observed in study participants. Furthermore, the study established a correlation between the clinically meaningful outcomes detected and modulations in those biomarkers. The Stage III natural history study analyzed blood samples from people living with ALS, treated with standard of care. Preliminary results show that levels of disease-related biomarkers remain steady and unchanged in people living with ALS, in contrast to the statistically significant decline portrayed in these biomarkers when PrimeC was administered in addition to the standard of care. Stage III results further confirmed PrimeC's MOA, and expanded insight into ALS- related biomarkers and their correlation to the progression of ALS symptoms.


© S&P Capital IQ 2022
All news about NEUROSENSE THERAPEUTICS LTD.
08/02NEUROSENSE THERAPEUTICS : Joins EverythingALS Open Innovation Consortium; Set to Enroll US..
PU
08/02NeuroSense Joins Everything ALS Open Innovation Consortium; Set to Enroll US and EU Pat..
CI
08/02NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Pati..
PR
08/01NEUROSENSE THERAPEUTICS : Report Of Foreign Private Issuer - Form 6-K
PU
07/28NEUROSENSE THERAPEUTICS : and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers ..
PU
07/28NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers..
PR
07/28NeuroSense Therapeutics Ltd. and NeuraLight Collaborate to Detect Amyotrophic Lateral S..
CI
07/18NEUROSENSE THERAPEUTICS : CEO Provides Key Corporate Update Video - Form 6-K
PU
07/18NeuroSense Therapeutics CEO Provides Key Corporate Update Video
PR
06/30Top Midday Gainers
MT
More news
Analyst Recommendations on NEUROSENSE THERAPEUTICS LTD.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -12,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,05x
Yield 2022 -
Capitalization 24,9 M 24,9 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 11
Free-Float 58,7%
Chart NEUROSENSE THERAPEUTICS LTD.
Duration : Period :
NeuroSense Therapeutics Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEUROSENSE THERAPEUTICS LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 2,13 $
Average target price 7,00 $
Spread / Average Target 229%
EPS Revisions
Managers and Directors
Alon Ben-Noon Chief Executive Officer & Director
Or Eisenberg Chief Financial Officer
Mark Wayne Leuchtenberger Chairman
Oron Yacoby-Zeevi Chief Scientific Officer
Ferenc Tracik Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NEUROSENSE THERAPEUTICS LTD.-13.41%25
GILEAD SCIENCES, INC.-13.29%78 912
VERTEX PHARMACEUTICALS34.12%75 532
REGENERON PHARMACEUTICALS, INC.-0.45%67 214
WUXI APPTEC CO., LTD.-20.10%40 830
BIONTECH SE-37.80%38 968